Invited Speakers


  1. Paul Attwood – University of Western Australia, Perth, Australia
    Protein Histidine Kinases as Potential Therapeutic Targets
  2. Dario Alessi – University of Dundee, Dundee, UK – confirmed
  3. Thomas Baumert – Université de Strasbourg, Strasbourg, France
    Chemoprevention of hepatocellular carcinoma targeting EGFR
  4. Richard Bayliss – University of Leicester, Leicester, UK
    The structural and functional consequences of protein phosphorylation
  5. Peter Blume-Jensen -XTuit Pharmaceuticals Inc., Waltham, US
    Microenviroment-Targeted Therapeutics and Predictive Biomarkers for Cancer and Fibrosis
  6. Krzysztof Brzózka – Selvita S.A., Cracow, Poland – confirmed
  7. Kim Choel – Baylor College of Medicine, Houston, US – confirmed
  8. Roger Daly – School of Biomedical Sciences, Monash University, Clayton, Australia
    Kinase and pseudokinase signalling networks in human cancer
  9. Wolfgang Dostman – College of Medicine, University of Vermont, Burlington, US
    Novel activators of type I cGMP-dependent protein kinase
  10. Michael Eck – Dana-Farber Cancer Institute, Harvard, USA – confirmed
  11. John Elkins – Universidade Estadual de Campinas – Unicamp, Campinas, Brazil
    Activation mechanism of Aurora B kinase
  12. Richard A. Engh – University of Tromso, Tromso, Norway
    “Protein kinase flexibility and inhibitor binding energies”
  13. Nathanael Gray – Dana-Farber Cancer Institute, Harvard, USA
  14. Fritz Herberg – University of Kassel, Kassel, Germany – confirmed
  15. Mien-Chie Hung – The University of Texas MD Anderson Cancer Center, Houston, USA – confirmed
  16. Natalia Jura – UC San Francisco, USA – confirmed
  17. Yasushi Kawaguchi – The University of Tokyo, Tokyo, Japan – confirmed
  18. Stefan Knapp – University of Oxford, Oxford, UK – confirmed
  19. Andrzej Kolinski – University of Warsaw, Poland – confirmed
  20. Eileen Kennedy – UC San Diego, USA
    Targeting AKAP signaling complexes with constrained peptide scaffolds
  21. Kannan Natarajan – University of Georgia, Athens, GA
    Investigating protein kinase mechanisms in the big data era
  22. Alexander Kornev – UC San Diego, USA – confirmed
  23. Gordon Langsley – Institut Cochin, Paris, France – confirmed
  24. Stefan Laufer – Tuebingen, Germany – confirmed
  25. Philip S. Low
    A New General Mechanism of Kinase Regulation of Membrane Transporters: Novel Opportunities for Therapeutic Interventions
  26. Mart Loog – University of Tartu, Tartu, Estonia – confirmed
  27. Jens Meiler – Vanderbilt University, Nashville, US – confirmed
  28. Kojo Mensa-Wilmot – University of Georgia, Athens, GA
    Trypanosome protein kinase inhibitors for biology and drug discovery
  29. Chris Murray – Astex, UK
    Computational and Fragment-based methods for the identification of kinase inhibitors
  30. Alexandra Newton – UC San Diego, USA – confirmed
  31. Ivan Plaza-Menacho – London Research Institute, London, UK – confirmed
  32. Lorenzo Pinna – University of Padova, Padova, Italy – confirmed
  33. Benoit Roux – University of Chicago, USA – confirmed
  34. Attila Remenya  Hungarian Academy of Sciences, Budapest, Hungary
    The molecular logic of MAP kinase mediated signaling: from structures to systems
  35. Andrew Shaw – Genentech, San Francisco, US
    Mechanisms of allosteric RAF kinase activation
  36. Kevan Shokat – University of California, San Francisco, US – confirmed
  37. Andrew Tobin – Universtiy of Glasgow, Glasgow, UK – confirmed
  38. Jack Taunton – UCSF School of Medicine, San Francisco, US
  39. Vincent Tagliabracci – Dept. of Molecular Biology at UT, Southwestern Medical Center in Dallas, US
    Novel atypical protein kinases
  40. Susan Taylor – UC San Diego, USA – confirmed
  41. Asko Uri – University of Tartu, Tartu, Estonia – confirmed
  42. Gianluigi Veglia – University of Minnesota, Minneapolis, US – confirmed

Comments are closed